Our Mission

A new Model to model Humans.

Only 10% of preclinical drug candidates are approved while 60% of approved drugs expand to additional indications. The same molecule can fail one trial and succeed in another, depending on the patient population, the indication, and the biological context. We model human response before the trial, helping teams find the indications, patients, and endpoints where the biology is most likely to work.

Contact

Capability

Find where a drug is most likely to work before Phase II makes the call. We model human response across patients, diseases, and endpoints to reveal clinical paths most likely to succeed.

Methodology

In silico clinical trials ran across patient cohorts at a fraction of cost, resources and time of traditional trials. We use your mechanism of action in our foundational model to predict effects on biomarkers, and clinical endpoints that surface the indications most likely to succeed.

Validation

Predictions compared against outcomes of traditional clinical programs. We measure accuracy continuously and improve as biology, patient data, and clinical evidence evolve.

Atlas foundational Model accurately captures Human Biology.

561 K

Patients to enroll into virtual clinical trials.

6.35 B

20 K

561 K

Patients to enroll into virtual clinical trials.

6.35 B20 K

Actively used to discover novel Insights.

The Founding Team.

A cross-functional team of scientists, engineers, and clinical experts building at the edge of AI and drug development. We work closely with pharma teams to translate mechanisms, patient biology, and clinical questions into predictive in silico trials, combining deep scientific review with fast, productized execution. The model does the heavy lifting. The team makes sure the biology is right.

Backed by the Best:

and Founders of the World's leading AI Labs.

Clinical Trials cost up to $1B. 90% of clinical Programs fail.

Unlock clinical precision at computational speed.